GlassScriptPhysician profile
Gabriel Pantol
NPI 1679733364
$50,536.13
in general payments reported to CMS, 2019-2025
63 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,361 · 2020: $11K · 2021: $26K · 2022: $5,328 · 2023: $1,830 · 2024: $1,531 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,366 · Consulting Fee: $300 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,366.34 |
| Consulting Fee | $300.00 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $13,062.27 | 2020-2021 | |
| Abbvie INC. | $11,269.67 | 2019-2025 | |
| Allergan, INC. | $9,868.84 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,643.15 | 2022 | |
| Alexion Pharmaceuticals, INC. | $2,589.70 | 2019-2025 | Ultomiris |
| Ucb, INC. | $1,008.52 | 2019-2025 | Rystiggo, Zilbrysq, Cimzia |
| Biogen, INC. | $866.73 | 2019-2025 | Tysabri |
| Novartis Pharmaceuticals Corporation | $865.07 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $835.21 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Amgen INC. | $694.63 | 2019-2025 | Aimovig |
| Genzyme Corporation | $602.13 | 2019-2022 | |
| Emd Serono, INC. | $554.69 | 2019-2025 | Mavenclad |
| Eisai INC. | $357.21 | 2019-2025 | |
| Csl Behring | $327.62 | 2019-2025 | Hizentra |
| Supernus Pharmaceuticals, INC. | $326.57 | 2019-2021 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Pantol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.